Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Refining functional phenotypes in an international cohort of untreated paediatric type 2 and 3 SMA patients using the Revised Hammersmith Scale.

Neuromuscular disorders : NMD·2026

Same author

Respiratory management in spinal muscular atrophy: development of a global outcome measure.

Neuromuscular disorders : NMD·2025

Same author

Assessing disease progression in spinal muscular atrophy, current gaps, and opportunities: a narrative review.

Neuromuscular disorders : NMD·2025

Same author

Mortality of symptomatic children with spinal muscular atrophy in the era of disease-modifying therapies.

Neuromuscular disorders : NMD·2025

Same author

Taking on the Titin: Muscle imaging as a diagnostic marker of biallelic <i>TTN-</i>related myopathy.

Journal of neuromuscular diseases·2025

Same author

Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6-48 months with Duchenne muscular dystrophy amenable to exon 51 skipping.

Neuromuscular disorders : NMD·2023

Same journal

Severe dilated cardiomyopathy in females with dystrophinopathy : a case series of nine patients.

Neuromuscular disorders : NMD·2026

Same journal

A portrait of facioscapulohumeral muscular dystrophy through history: past milestones and future challenges on the road to understanding and treatment.

Neuromuscular disorders : NMD·2026

Same journal

Systematic review of outcome measures in facioscapulohumeral dystrophy (FSHD): validated, usable, and feasible tools for assessing function, performance, and strength.

Neuromuscular disorders : NMD·2026

Same journal

Longitudinal functional trajectories in Duchenne muscular dystrophy: outcome-specific patterns from a registry-based modelling study.

Neuromuscular disorders : NMD·2026

Same journal

HACD1-related congenital myopathy skeletal muscle MRI findings in a Brazilian cohort.

Neuromuscular disorders : NMD·2026

Same journal

Sensory abnormalities and entrapment neuropathies identified by nerve conduction studies in patients with amyotrophic lateral sclerosis.

Neuromuscular disorders : NMD·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 27, 2026

Picrosirius Red Staining for Semiquantitative Histopathologic Evaluation of Collagen Deposition in Murine Models of Chronic Lung Allograft Rejection

Picrosirius Red Staining for Semiquantitative Histopathologic Evaluation of Collagen Deposition in Murine Models of Chronic Lung Allograft Rejection

Published on: March 21, 2025

Flow cytometry analysis: a quantitative method for collagen VI deficiency screening.

J Kim¹, C Jimenez-Mallebrera, A R Foley

¹Dubowitz Neuromuscular Centre, University College London Institute of Child Health, London, UK.

Neuromuscular Disorders : NMD

|November 15, 2011

Summary

This summary is machine-generated.

Flow cytometry offers a quantitative method to measure collagen VI protein levels, aiding in the diagnosis of collagen VI myopathies like Ullrich congenital muscular dystrophy and Bethlem myopathy.

More Related Videos

Quantifying Fibrillar Collagen Organization with Curvelet Transform-Based Tools

Quantifying Fibrillar Collagen Organization with Curvelet Transform-Based Tools

Published on: November 11, 2020

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Related Experiment Videos

Last Updated: May 27, 2026

Picrosirius Red Staining for Semiquantitative Histopathologic Evaluation of Collagen Deposition in Murine Models of Chronic Lung Allograft Rejection

Picrosirius Red Staining for Semiquantitative Histopathologic Evaluation of Collagen Deposition in Murine Models of Chronic Lung Allograft Rejection

Published on: March 21, 2025

Quantifying Fibrillar Collagen Organization with Curvelet Transform-Based Tools

Quantifying Fibrillar Collagen Organization with Curvelet Transform-Based Tools

Published on: November 11, 2020

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Area of Science:

Biochemistry
Genetics
Cell Biology

Background:

Mutations in COL6A1, COL6A2, and COL6A3 genes cause collagen VI myopathies, including Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM).
Current diagnostic methods for collagen VI expression lack quantitative accuracy, making subtle expression changes difficult to detect.

Purpose of the Study:

To investigate flow cytometry as a quantitative method for measuring collagen VI protein expression in primary fibroblasts.
To compare the efficacy of flow cytometry with standard immunohistochemical analysis for diagnosing collagen VI myopathies.

Main Methods:

Primary fibroblasts from eight UCMD patients, five BM patients, and five controls were analyzed.
Collagen VI expression was measured using flow cytometry and compared to standard fibroblast collagen VI immunohistochemical analysis.

Main Results:

Flow cytometry consistently detected a significant reduction (≥60%) in collagen VI in all UCMD cases.
BM cases showed variable but on average 20% less collagen VI compared to controls.
Flow cytometry provided a quantitative assessment of collagen VI protein levels.

Conclusions:

Flow cytometry is a viable alternative method for quantitatively screening collagen VI deficiency at the protein level.
This method is time- and cost-effective for diagnosing collagen VI myopathies.
Flow cytometry enhances the diagnostic capabilities for collagen VI-related muscle disorders.